The
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
(Nasdaq Global Market)
|
Item 7.01 |
Regulation FD Disclosure.
|
Item 9.01. |
Financial Statements and Exhibits.
|
Exhibit
No.
|
Description
|
|
Investor Presentation, dated January 4, 2024.
|
||
104
|
Cover Page Interactive Data File (embedded within the inline XBRL document).
|
|
*
|
Furnished herewith.
|
ATAI LIFE SCIENCES N.V.
|
||
Date: January 4, 2024
|
By:
|
/s/ Florian Brand
|
Name:
|
Florian Brand
|
|
Title:
|
Chief Executive Officer
|